These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
2 files

Structure-Reactivity Relationships on Substrates and Inhibitors of the Lysine Deacylase Sirtuin 2 from Schistosoma Mansoni (SmSirt2)

revised on 02.08.2019, 06:42 and posted on 02.08.2019, 16:29 by Daria Monaldi, Dante Rotili, Julien Lancelot, Martin Marek, Nathalie Wössner, Alessia Lucidi, Daniela Tomaselli, Elizabeth Ramos-Morales, Christophe Romier, Raymond J. Pierce, Antonello Mai, Manfred Jung
The only drug for treatment of Schistosomiasis is Praziquantel, and the possible emergence of resistance makes research on novel therapeutic agents necessary. Targeting of Schistosoma mansoni epigenetic enzymes, which regulate the parasitic life cycle, emerged as promising approach. Due to the strong effects of human Sirtuin inhibitors on parasite survival and reproduction, Schistosoma sirtuins were postulated as therapeutic targets. In vitro testing of synthetic substrates of S. mansoni Sirtuin 2 (SmSirt2) and kinetic experiments on a myristoylated peptide demonstrated lysine long chain deacylation as an intrinsic SmSirt2 activity for the first time. Focused in vitro screening of the GSK Kinetobox library and structure-activity relationships (SAR) of identified hits, led to the first SmSirt2 inhibitors with activity in the low micromolar range. Several SmSirt2 inhibitors showed potency against both larval schistosomes (viability) and adult worms (pairing, egg laying) in culture without general toxicity to human cancer cells.


Email Address of Submitting Author


University of Freiburg



ORCID For Submitting Author


Declaration of Conflict of Interest

No conflict of interest

Version Notes

1.0 Original Submission 2.0 Revised version (hSirt13 selectivity, kinetic data on lysine substrates added)